Through analyses of the complex underlying issues, this interdisciplinary volume frames the agenda for dealing with genetic variation and incorporating pharmacogenomics into health care. The three sections of this book, Research Issues, Clinical Issues, and Social Perspectives  address key elements integral to a comprehensive discussion of this emerging field.
This groundbreaking text…
- Examines new research strategies, methodologies, and ethical and social considerations of pharmacogenomics
- Addresses practical considerations of anticipated changes in education, training, oversight, guidelines and protocols, and continuing education requirements
- Provides analyses of the potential enormous impact of pharmacogenomics, such as in the standard of care and treatment, including perspectives from the fields of anthropology, law, ethics, and economics
Foreword (F. Collins).
Preface.
PART I: INTRODUCTION: SCIENCE AND SOCIETY.
Public Attitudes About Pharmacogenomics (M. Rothstein, et al.).
Pharmacogenomics:  Pharmacology and Toxicology in the Genomics (H. Mohrenweiser).
The Implications of Population Genetics for Pharmacogenomics (C. Hanis).
PART II: RESEARCH AND DEVELOPMENT CHALLENGES AND CONSIDERATIONS.
Genome Research and Minorities (H. Greely).
Drug Development Strategies (P. Manasco & T. Arledge).
Drug Development,  Regulation, and Genetically Guided Therapy Pharmacogenomics (D. Feigal & S. Gutman).
Intellectual Property and Commercial Aspects of Pharmacogenomics (A. Nunnally,  et al.).
PART III: CLINICAL APPLICATIONS.
Integration of PhalS